Leukemia
It is recommended that most patients with CLL receive the COVID-19 vaccine, although each patient should still talk with their healthcare team first. Read More ›
A new laboratory-based scoring system may allow physicians to better predict which patients with early-stage CLL are most likely to require early treatment. Read More ›
Patients with CLL may be at increased risk for developing severe COVID-19. Experts have provided insights on how to protect them while still delivering optimal care. Read More ›
Updated National Comprehensive Cancer Network (NCCN) guidelines now recommend zanubrutinib as alternative first- and second-line therapy for some patients. Read More ›
Cannabis compounds such as cannabidiol have shown cancer-fighting activity in the lab. What should patients know? Read More ›
A new model of the symptoms and impacts faced by patients may lead to better clinical tools for understanding the patient experience. Read More ›
Patients who are in a period of active observation should feel comfortable sharing anything that seems abnormal with their healthcare provider. Read More ›
A greater number of comorbidities alone may not be sufficient to predict patient survival; age and stage at diagnosis must be considered as well. Read More ›
The first phase 3 trial comparing these drugs shows that acalabrutinib has similar efficacy as ibrutinib with a lower risk of a worrisome side effect. Read More ›
Although the use of telemedicine has been increasing due to the COVID-19 pandemic, it has not completely replaced the need for in-person visits. Read More ›